Keybank National Association OH Purchases 60,375 Shares of Illumina, Inc. $ILMN

Keybank National Association OH increased its position in Illumina, Inc. (NASDAQ:ILMN) by 17.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 399,621 shares of the life sciences company’s stock after purchasing an additional 60,375 shares during the period. Keybank National Association OH owned approximately 0.26% of Illumina worth $37,952,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. National Pension Service raised its holdings in Illumina by 29.4% during the third quarter. National Pension Service now owns 46,284 shares of the life sciences company’s stock worth $4,396,000 after buying an additional 10,529 shares during the last quarter. AlphaQuest LLC increased its position in shares of Illumina by 181.4% during the third quarter. AlphaQuest LLC now owns 1,559 shares of the life sciences company’s stock worth $148,000 after acquiring an additional 1,005 shares in the last quarter. Arizona State Retirement System raised its holdings in shares of Illumina by 1.8% in the 3rd quarter. Arizona State Retirement System now owns 47,089 shares of the life sciences company’s stock worth $4,472,000 after acquiring an additional 832 shares during the last quarter. Impact Partnership Wealth LLC bought a new position in Illumina in the 3rd quarter valued at about $744,000. Finally, Capital Investment Services of America Inc. boosted its stake in Illumina by 3.4% during the 3rd quarter. Capital Investment Services of America Inc. now owns 93,439 shares of the life sciences company’s stock valued at $8,874,000 after purchasing an additional 3,069 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Insiders Place Their Bets

In related news, insider Scott M. Davies sold 323 shares of Illumina stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the completion of the sale, the insider owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. This trade represents a 1.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Scott Gottlieb acquired 500 shares of the stock in a transaction that occurred on Monday, November 3rd. The stock was purchased at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the purchase, the director directly owned 12,523 shares in the company, valued at $1,529,433.99. This trade represents a 4.16% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 2.60% of the company’s stock.

Illumina Stock Down 3.3%

Illumina stock opened at $144.81 on Friday. The firm has a 50 day moving average price of $138.08 and a 200-day moving average price of $114.91. The company has a quick ratio of 1.12, a current ratio of 1.43 and a debt-to-equity ratio of 0.42. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $155.53. The company has a market capitalization of $22.13 billion, a P/E ratio of 32.47, a P/E/G ratio of 2.48 and a beta of 1.41.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The company had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the previous year, the firm posted $1.14 EPS. Illumina’s revenue was up .4% on a year-over-year basis. As a group, equities analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on ILMN shares. JPMorgan Chase & Co. raised their target price on Illumina from $105.00 to $130.00 and gave the company a “neutral” rating in a report on Monday, December 15th. Robert W. Baird set a $109.00 price objective on shares of Illumina in a report on Friday, October 31st. Zacks Research downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 31st. Wall Street Zen raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Illumina in a research report on Wednesday, January 7th. Six investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $127.18.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.